novel evidence that inhibition of BMP-2 or BMP-2-mediated MAPK/Runx2/Snail signaling is an attractive therapeutic target for osteolytic bone metastases in lung cancer patients.

RUNX2 overexpression is associated with nonsmall cell lung cancer.

downregulation of miR-218 may contribute to the chemoresistance of non-small cell lung cancer cells to cisplatin, which leads to upregulation of RUNX2

WWOX expression was strongly inhibited in human lung cancers and lung cancer cell lines. Reintroducing WWOX into lung cancer cells inhibited their invasive phenotype through downregulating RUNX2 and its target genes including MMP-9 expression.

RUNX2 increased expression is associated with metastasis and epithelial mesenchymal transition in non-small cell lung cancer lung cancer.

microRNA-23B inhibits non-small cell lung cancer proliferation, invasion and migration via downregulation of RUNX2 and inhibition of Wnt/Beta-catenin signaling pathway.

The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.

Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism.

Here we show that Runx2 is highly expressed in lung cancer cells and downregulates BMP-3B. The ectopic expression of Runx2, but not DNA binding mutant Runx2, in normal lung fibroblast cells and lung cancer cells resulted in suppression of BMP-3B levels.